ArticleBritish journal of cancer2019
Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases.
Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Pooled it
- Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Intra- and intertumoral discordance of Claudin-18.2: a systematic review and meta-analysis.ESMO gastrointestinal oncology · 2026Review
- Intratumoral heterogeneity of intermediate CLDN18.2 expression in gastric cancer.International journal of clinical oncology · 2026Article
- Claudin 18.2 expression-concordance between primary and metastatic lesions in gastric and gastroesophageal adenocarcinomas: a systematic review and meta-analysis.ESMO gastrointestinal oncology · 2026Review
- Claudin-18.2 in Gastric and Gastroesophageal Junction Adenocarcinoma: From Biology to Therapeutic Targeting: A Narrative Review.Targeted oncology · 2026Review
- Claudin 18.2 Expression and Outcomes of First-Line Chemoimmunotherapy in HER2-Negative Gastric or Gastroesophageal Junction Cancer: A Single-Center Retrospective Study.Current oncology (Toronto, Ont.) · 2026Article
- Histological and biomarker landscape of Claudin18.2-positive gastric and gastroesophageal junction cancers: a study of 937 cases.Virchows Archiv : an international journal of pathology · 2026Article
- Article
- Efficacy of CLDN18.2-Targeted Radiotheranostics in Patient-Derived Models of Gastric Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies.Journal of hematology & oncology · 2026Review
- Claudin-18 expression in gastric type adenocarcinoma and HPV-associated adenocarcinoma of the uterine cervix.Histopathology · 2026Article
- Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer.International journal of clinical oncology · 2026Article
- Molecular imaging in gastric cancer: state-of-the-art techniques and emerging opportunities.Journal of translational medicine · 2026Review
- GPA33 forms a distinct diagnostic target class to Claudin 18.2 in oesophageal adenocarcinoma enabling the development of a novel GPA33 antibody-based detection platform.Cellular & molecular biology letters · 2026Article
- Clinicopathologic correlates of claudin 18.2 expression in esophagogastric cancer at multiple expression levels.ESMO gastrointestinal oncology · 2026Article
- Claudin18.2 promote gastric cancer proliferation by activating MCM2/5.Scientific reports · 2026Article
- Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites.World journal of gastrointestinal oncology · 2026Article
- Molecular Subtypes of Mixed Gastric Cancer Defined by Machine Learning for Predicting Prognosis and Treatment Response.Current medicinal chemistry · 2026Article
- Claudin 18.2 Expression in Gastric Adenocarcinoma: Diagnostic Reproducibility and Clinicopathologic Associations in A Western Cohort.Oncology research · 2026Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundClaudin-18 (CLDN18) is a highly specific tight junction protein of the gastric mucosa. An isoform of CLDN18, the Claudin 18.2, has recently emerged as an innovative drug target for metastatic gastric cancer.
methodsWe investigated the immunohistochemical profile of CLDN18, p53, p16, E-cadherin, MSH2, MSH6, MLH1, PSM2, HER2, and PDL-1 in a large series of 523 primary gastric carcinomas (GCs; n = 408) and gastro-oesophageal carcinomas (GECs; n = 115) and 135 matched and synchronous nodal metastases. The status of HER2 and EBER by means of chromogenic in situ hybridisation (CISH) was also evaluated.
resultsHigh membranous CLDN18 expression was present in 150/510 (29.4%) primary cases and in 45/132 (34.1%) metastases. An abnormal expression (i.e. nuclear and/or cytoplasmic) was observed in 115 (22.5%) primary cases and in 33 (25.0%) metastases. A 38.8% of the cases showed significant CLDN18 intratumoural variability among the different tissue microarray cores obtained from the same tumour. Positive membrane CLDN18 expression was statistically associated with non-antral GCs (p = 0.016), Lauren diffuse type (p = 0.009), and with EBV-associated cancers (p < 0.001).
conclusionsCLDN18 is frequently expressed in gastric and gastro-oesophageal cancers; further studies should investigate the prognostic significance of CLDN18 heterogeneity in order to implement its test into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.